Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Multiplex IHC as biomarkers for cancer immunotherapy

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.05.16
Views: 2103

Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA

Dr Paul Tumeh speaks with ecancertv at AACR 2016 about determining potential biomarkers using multiplexed immunohistochemistry.

Having created a spatially resolved model of the tumour microenvironment in all its heterogeneity, with different cell types identified by coloured labels, Dr Tumeh describes visible tracking of a tumour responding to immunotherapy.

As such, he explains how multiple biomarkers are a necessary course for increased drug efficacy, and that a negative assay response to one biomarker need not be a prognostic limitation.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation